Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale
SAN DIEGO — Scientists have long dreamed of creating vaccine-like treatments that could teach the immune system to target tumors. After decades of false starts, that idea is finally getting closer to reality.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound and CleanSpark
Janux Announces Pricing of $296.5 Million Underwritten Public Offering
Janux Therapeutics surges on upbeat trial data for prostate cancer therapy
Janux Therapeutics Announces Proposed Public Offering of Common Stock
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors